|  |  |
| --- | --- |
| 09-82918_logo_E_RGB  **International Narcotics Control Board** | **FORM P** 43rd Edition, July 2023 |

**ANNUAL STATISTICAL REPORT ON SUBSTANCES LISTED IN THE**

**CONVENTION ON PSYCHOTROPIC SUBSTANCES OF 1971**

**(to be furnished to the International Narcotics Control Board (INCB) pursuant to Convention on   
Psychotropic Substances of 1971: articles 1, 2, 3, 12 and 16**

**Resolution I of the United Nations Conference for the Adoption of a Protocol on Psychotropic Substances, Economic and Social Council resolutions 1576 (L), 1985/15, 1987/30 and Commission on Narcotic Drugs resolution 54/6)**

|  |  |  |  |
| --- | --- | --- | --- |
| **Country or Territory:** |  | **Date:** |  |
| **Competent office:** |  | | |
| **Title or function:** |  | | |
| **Responsible officer’s name:** |  | **Email:** |  |
| **Telephone number(s):** |  | **Fax number(s):** |  |
| **Signature:** |  | **Calendar year:** |  |

|  |
| --- |
| **CHANGES IN UNIT OF MEASURE**  **To facilitate more consistent data reporting it is requested that KILOGRAMS (KG) be used for ALL substances (Schedules I, II, III and IV) in all parts of Form P.** |

|  |
| --- |
| **The present form can also be downloaded from the INCB website:**  **www.incb.org, under “Psychotropic Substances”, Toolkit: “Form P”**  **Please consider submitting this form using XML format or MS Excel format.** |

|  |
| --- |
| The present form should be completed as soon as possible and not later than 30 June of the year following  the year to which the statistical data relate. This form should be completed and sent to:  International Narcotics Control Board  Vienna International Centre  P.O. Box 500, A-1400 Vienna, Austria  Telephone: + (43) (1) 26060-4277 Facsimile: + (43) (1) 26060-5867 or 26060-5868  Email: incb.secretariat@un.org, incb.psychotropics@un.org Home page: [www.incb.org](http://www.incb.org) |

**Remarks**

|  |
| --- |
|  |

Instructions

(to be read carefully before completing the form)

General

1. All psychotropic substances under international control are listed in the annex to the annual statistical report (“Green List”), which is distributed to Governments annually by the International Narcotics Control Board (INCB).

2. This form is divided into three parts:

Part one. Statistical data on the manufacture, utilization, stocks, imports, exports and consumption of substances in Schedules I, II, III and IV of the 1971 Convention and their salts;

Part two. Trade details: statistical data on imports and exports of substances in Schedules I, II, III and IV of the   
1971 Convention;

Part three. Statistical data on the use of substances in Schedules I, II, III and IV of the 1971 Convention for the manufacture of other psychotropic substances.

3. In order to ensure the accurate completion of the form, it should be borne in mind that the terms used have the same meanings as those given in article 1 of the Convention on Psychotropic Substances of 1971, for example:

(a) “Export” and “import” mean in their respective connotations the physical transfer of a psychotropic substance from one State to another State;

(b) “Manufacture” means all processes by which psychotropic substances may be obtained, and includes refining as well as the transformation of psychotropic substances into other psychotropic substances. The term also includes the making of preparations other than those made on prescription in pharmacies;

(c) “Psychotropic substance” means any substance, natural or synthetic, or any natural material in Schedule I, II, III or IV of the Convention. The schedules are amended from time to time according to a procedure established in article 2 of the Convention;

(d) “Region” means any part of a State that, pursuant to article 28, is treated as a separate entity for the purposes of the Convention. The term “region” corresponds to the term “territory” used in the other statistical forms of INCB;

(e) “Schedule I”, “Schedule II”, “Schedule III” and “Schedule IV” mean the correspondingly numbered lists of psychotropic substances annexed to the Convention, as altered in accordance with article 2.

4. The statistical data entered on the form should be expressed in terms of the pure anhydrous base of each psychotropic substance contained in salts and preparations, excluding the weight of any non-psychotropic substance that may be combined or mixed with it. The weight should be reported in kilograms for psychotropic substances listed in Schedules I, II, III and IV. A table of the conversion factors needed to convert quantities of psychotropic substances in salt form into quantities of pure anhydrous base content is provided in part two of the “Green List”.

5. In the case of preparations containing two or more psychotropic substances, data relating to each substance should be entered separately.

Remarks

6. In the space provided for remarks on page 1, the reporting authority may communicate to INCB any information facilitating the proper understanding of the reported statistical data. Such information may, for example, refer to a substance that was put under international control only during the year to which the report relates, in which case the reporting authority may wish to inform INCB that statistical data relating to that substance cover only the period following the date on which the inclusion of the substance in the relevant schedule of the 1971 Convention became fully effective (see article 2 of the Convention) and not the whole calendar year. Other information such as losses in the manufacturing process or seizures of psychotropic substances may also be reported under “Remarks”.

**Part one. Statistical data on the manufacture, utilization, stocks, imports, exports and consumption of substances in Schedules I, II, III and IV of the 1971 Convention and their salts**

Column 1 (Substance)

7. The psychotropic substances are referred to either by their international non-proprietary names (INN) or by the other non‑proprietary or trivial names indicated in the schedules of the 1971 Convention. The chemical name of each psychotropic substance may also be found in the schedules or in part one of the “Green List”.

Column 2 (Quantity manufactured)

8. For each psychotropic substance, the reporting authority should indicate the total quantity manufactured domestically between 1 January and 31 December of the year to which the statistical data relate. The quantities of psychotropic substances used for the preparation of pharmaceutical dosage forms should not be included under column 2 (Quantity manufactured). However, in the case of a continuous manufacturing process that does not go through the intermediate stage of the manufacture of psychotropic substances in bulk form, but uses non-psychotropic starting material and directly leads to the final preparations containing psychotropic substances, the data on quantities manufactured under column 2 should include the quantities of the psychotropic substances contained in the manufactured preparations.

Column 3 (Quantity used for the manufacture of non-psychotropic substances or products)

9. For each psychotropic substance listed in Schedules II, III and IV, the reporting authority should indicate the quantity used for the manufacture of non-psychotropic substances or products (permitted under article 4, paragraph (b), of the 1971 Convention). That quantity should include the total amount placed in the manufacturing process during the year to which the statistical data relate, even if the manufacturing process was not completed by the end of that year. Not applicable for substances in Schedule I.

Column 4 (Quantity used for the manufacture of preparations exempted under article 3, paragraphs 2 and 3)

10. For each psychotropic substance listed in Schedules II and III, the reporting authority should indicate the total quantity used for manufacture of preparations exempted from certain measures of control (permitted under article 3, paragraphs 2 and 3, of the 1971 Convention). That quantity should include the total amount placed in the manufacturing process during the year to which the statistical data relate, even if the manufacturing process was not completed by the end of that year. The quantities reported with respect to substances in Schedule II and III should be expressed in kilograms. Figures for psychotropic substances in Schedule IV may also be reported (in kilograms). Not applicable for substances in Schedule I.

Column 5 (Manufacturers’ stocks as at 31 December)

11. For each psychotropic substance listed in Schedules I, II, III and IV, the reporting authority should indicate the quantity held in stock by manufacturers on 31 December of the year to which the statistical data relate in kilograms.

Columns 6 (Imports) and 7 (Exports)

12. Statistical data should be based, to the extent possible, on actual movements across borders.

13. For each psychotropic substance listed in Schedules I and II, the reporting authority should indicate (in kilograms) the total quantity imported in column 6 and the total quantity exported in column 7; these quantities must be detailed by country or region of origin in section V and by country or region of destination in section VI.

14. For each psychotropic substance listed in Schedules III and IV, the reporting authority should indicate (in kilograms) the total quantity imported in column 6 and the total quantity exported in column 7. Pursuant to Economic and Social Council resolution 1985/15 of 28 May 1985, the quantities reported in column 6 may be detailed by country or region of origin in section VII, entitled “Trade details: import of substances in Schedules III and IV, by country or region of origin”, and the quantities reported in column 7 may be detailed by country or region of destination in section VIII, entitled “Trade details: export of substances in Schedules III and IV, by country or region of destination”.

Column 8 (Consumption)

15. Pursuant to Commission on Narcotic Drugs resolution 54/6, for each psychotropic substance listed in Schedules I, II, III and IV, the reporting authority should indicate (in kilograms) the quantity consumed during the year in question, i.e., supplied to any person or enterprise for retail distribution, medical use or scientific research.

**Part two. Trade details: statistical data on imports and exports of substances in   
Schedules I, II, III and IV of the 1971 Convention**

16. The term “import”, as used in the 1971 Convention, is intended to include, as far as possible, the entrance of goods from abroad into a bonded warehouse, free port or free zone; similarly, the term “export” is intended to include the dispatch of goods abroad from a bonded warehouse, free port or free zone, although such transactions may not be treated by the national customs laws as imports and exports. However, care should be taken to ensure that goods passing through customs from a bonded warehouse, free port or free zone into the country or region itself are not recorded as imports, and that goods transferred from the country or region itself into a bonded warehouse, free port or free zone situated in the country or region are not recorded as exports. However, if a consignment passes in transit through a country or region to another country, it should not be considered by the country or region through which it passes as an import and subsequent export, even if the consignment is placed temporarily in a bonded warehouse, free port or free zone.

17. Goods returned by a country or region, for any reason whatsoever, to the original exporting country or region shall be entered as an export by the former and as an import by the latter.

18. In section V, entitled “Trade details: import of substances in Schedules I and II, by country or region of origin”, for each substance listed in Schedules I and II, indicate the name of the substance, the total quantity imported as reported in column 6 (in kilograms) in sections I and II and, under “Imported from”, the name of the exporting country or region.

19. In section VI, entitled “Trade details: export of substances in Schedules I and II, by country or region of destination”, for each of the substances reported in Schedules I and II, indicate the name of the substance, the total quantity exported as reported in column 7 (in kilograms) in sections I and II and, under “Exported to”, the name of the importing country or region.

20. In section VII, entitled “Trade details: import of substances in Schedules III and IV, by country or region of origin”, pursuant to Economic and Social Council resolution 1985/15 of 28 May 1985, for each of the substances reported in Schedules III and IV, indicate the name of the substance, the total quantity imported as reported in column 6 (in kilograms) in sections III and IV and, under “Imported from”, the name of the exporting country or region.

21. In section VIII, entitled “Trade details: export of substances in Schedules III and IV, by country or region of destination”, pursuant to Economic and Social Council resolution 1985/15 of 28 May 1985, for each of the substances reported in Schedules III and IV, indicate the name of the substance, the total quantity exported as reported in column 7 (in kilograms) in sections III and IV and, under “Exported to”, the name of the importing country or region.

**Part three. Statistical data on the use of substances in Schedules I, II, III and IV of the   
1971 Convention for the manufacture of other psychotropic substances**

22. Countries and territories are requested to provide information, on a voluntary basis, on the use of psychotropic substances listed in Schedules I, II, III and IV for the manufacture of other psychotropic substances, indicating the name of the source substance, the quantity used in the manufacturing process, the name of the other psychotropic substance derived from the manufacturing process and the quantity of that substance derived from the manufacturing process.

**Part one. Statistical data on the manufacture, utilization, stocks, imports, exports and consumption of substances in Schedules I, II, III and IV of the 1971 Convention and/or their salts**

**I. Statistical data on substances in Schedule I and/or their salts**

(Kilograms)

|  | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| IDS Code | Substance | Quantity manufactured | Quantity used for the manufacture of non-psychotropic substances or products | Quantity used for the manufacture of preparations exempted under article 3, paragraphs 2 and 3 | Manufacturers’ stocks as at 31 December | Total imports (these quantities must be detailed by country or region of origin in section V) | Total exports (these quantities must be detailed by country or region of destination in section VI) | Quantity consumed |
| PC 010 | Cathinone |  | (Not applicable) | |  |  |  |  |
| PD 001 | DET |  |  |  |  |  |
| PD 003 | DMHP |  |  |  |  |  |
| PD 004 | DMT |  |  |  |  |  |
| PD 007 | DMA |  |  |  |  |  |
| PD 008 | DOET |  |  |  |  |  |
| PD 009 | Brolamfetamine (DOB) |  |  |  |  |  |
| PD 011 | DOC |  |  |  |  |  |
| PE 006 | Etryptamine |  |  |  |  |  |
| PL 002 | (+)-Lysergide (LSD or  LSD-25) |  |  |  |  |  |
| PM 004 | Mescaline |  |  |  |  |  |
| PM 011 | MDMA |  |  |  |  |  |
| PM 013 | MMDA |  |  |  |  |  |
| PM 014 | Tenamfetamine (MDA) |  |  |  |  |  |
| PM 017 | 4-methylaminorex |  |  |  |  |  |
| PM 019 | Methcathinone |  |  |  |  |  |
| PM 020 | 4-MTA |  |  |  |  |  |
| PN 004 | N-ethyl-MDA (MDEA) |  |  |  |  |  |
| PN 005 | N-hydroxy MDA |  |  |  |  |  |
| PN 006 | 25B-NBOMe |  |  |  |  |  |
| PN 007 | 25C-NBOMe |  |  |  |  |  |
| PN 008 | 25I-NBOMe |  |  |  |  |  |
| PP 001 | Parahexyl |  |  |  |  |  |
| PP 003 | Eticyclidine (PCE) |  |  |  |  |  |
| PP 007 | Rolicyclidine (PHP or PCPY) |  |  |  |  |  |
| PP 012 | Psilocine or psilotsin |  |  |  |  |  |
| PP 013 | Psilocybine |  |  |  |  |  |
| PP 017 | PMA |  |  |  |  |  |
| PP 021 | PMMA |  |  |  |  |  |
| PS 002 | STP, DOM |  |  |  |  |  |
| PT 001 | Tenocyclidine (TCP) |  |  |  |  |  |
| PT 002 | Tetrahydrocannabinol, the following isomers and their stereochemical variants: ∆6a(10a),∆6a(7), ∆7, ∆8, ∆10 and ∆9(11) |  |  |  |  |  |
| PT 006 | TMA |  |  |  |  |  |

**II. Statistical data on substances in Schedule II and/or their salts**

(Kilograms)

|  | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| IDS Code | Substance | Quantity manufactured | Quantity used for the manufacture of non-psychotropic substances or products | Quantity used for the manufacture of preparations exempted under article 3, paragraphs 2 and 3 | Manufacturers’ stocks as at 31 December | Total imports (these quantities must be detailed by country or region of origin in section V) | Total exports (these quantities must be detailed by country or region of destination in section VI) | Quantity consumed |
| PA 003 | Amfetamine |  |  |  |  |  |  |  |
| PA 007 | Amineptine |  |  |  |  |  |  |  |
| PA 008 | AM-2201 |  |  |  |  |  |  |  |
| PA 009 | 5F-APINACA (5F-AKB-48) |  |  |  |  |  |  |  |
| PA 010 | 5F-AMB (5F-AMB-PINACA) |  |  |  |  |  |  |  |
| PA 011 | ADB-BUTINACA |  |  |  |  |  |  |  |
| PB 008 | 2C-B |  |  |  |  |  |  |  |
| PC 011 | AB-CHMINACA |  |  |  |  |  |  |  |
| PC 012 | CUMYL-4CN-BINACA |  |  |  |  |  |  |  |
| PC 013 | ADB-CHMINACA (MAB-CHMINACA) |  |  |  |  |  |  |  |
| PC 014 | 4-CMC (clephedrone) |  |  |  |  |  |  |  |
| PC 015 | CUMYL-PEGACLONE |  |  |  |  |  |  |  |
| PD 002 | Dexamfetamine |  |  |  |  |  |  |  |
| PD 010 | Dronabinol (*delta*-9-THC[[1]](#footnote-2)\*) |  |  |  |  |  |  |  |
| PD 012 | Diphenidine |  |  |  |  |  |  |  |
| PE 007 | Ethylone |  |  |  |  |  |  |  |
| PE 008 | Ethylphenidate |  |  |  |  |  |  |  |
| PE 010 | Eutylone |  |  |  |  |  |  |  |
| PF 005 | Fenetylline |  |  |  |  |  |  |  |
| PF 007 | 4-Fluoroamphetamine  (4-FA) |  |  |  |  |  |  |  |
| PF 008 | FUB-AMB  (MMB-FUBINACA,  AMB-FUBINACA) |  |  |  |  |  |  |  |
| PF 009 | ADB-FUBINACA |  |  |  |  |  |  |  |
| PF 010 | AB-FUBINACA |  |  |  |  |  |  |  |
| PG 002 | GHB |  |  |  |  |  |  |  |
| PJ 001 | JWH-018 |  |  |  |  |  |  |  |
| PL 006 | Levamfetamine |  |  |  |  |  |  |  |
| PL 007 | Levomethamphetamine |  |  |  |  |  |  |  |
| PM 002 | Mecloqualone |  |  |  |  |  |  |  |
| PM 005 | Metamfetamine |  |  |  |  |  |  |  |
| PM 006 | Methaqualone |  |  |  |  |  |  |  |
| PM 007 | Methylphenidate |  |  |  |  |  |  |  |
| PM 015 | Metamfetamine racemate |  |  |  |  |  |  |  |
| PM 021 | MDPV |  |  |  |  |  |  |  |
| PM 022 | Mephedrone |  |  |  |  |  |  |  |
| PM 023 | Methylone (*beta*-keto-MDMA) |  |  |  |  |  |  |  |
| PM 024 | Methoxetamine |  |  |  |  |  |  |  |
| PM 025 | MDMB-CHMICA |  |  |  |  |  |  |  |
| PM 026 | Methiopropamine |  |  |  |  |  |  |  |
| PM 027 | 4-Methylethcathinone  (4-MEC) |  |  |  |  |  |  |  |
| PM 028 | 5F-MDMB-PICA |  |  |  |  |  |  |  |
| PM 029 | 4F-MDMB-BINACA |  |  |  |  |  |  |  |
| PM 030 | MDMB-4en-PINACA |  |  |  |  |  |  |  |
| PM 031 | 3-Methoxyphencyclidine |  |  |  |  |  |  |  |
| PM 032 | 3-Methylmethcathinone |  |  |  |  |  |  |  |
| PN 009 | *N*-benzylpiperazine (BZP) |  |  |  |  |  |  |  |
| PN 010 | *N*-ethylnorpentylone (ephylone) |  |  |  |  |  |  |  |
| PN 011 | *N-*ethylhexedrone |  |  |  |  |  |  |  |
| PP 005 | Phencyclidine (PCP) |  |  |  |  |  |  |  |
| PP 006 | Phenmetrazine |  |  |  |  |  |  |  |
| PP 011 | 5F-ADB/5F-MDMB-PINACA |  |  |  |  |  |  |  |
| PP 018 | AB-PINACA |  |  |  |  |  |  |  |
| PP 022 | *alpha*-PVP |  |  |  |  |  |  |  |
| PP 023 | 4,4’-DMAR |  |  |  |  |  |  |  |
| PP 025 | Pentedrone |  |  |  |  |  |  |  |
| PP 026 | 5F-PB-22 |  |  |  |  |  |  |  |
| PP 027 | *alpha*-PHP |  |  |  |  |  |  |  |
| PP 028 | *alpha*-PiHP |  |  |  |  |  |  |  |
| PS 001 | Secobarbital |  |  |  |  |  |  |  |
| PU 001 | UR-144 |  |  |  |  |  |  |  |
| PX 001 | XLR-11 |  |  |  |  |  |  |  |
| PZ 001 | Zipeprol |  |  |  |  |  |  |  |

\* This refers to *delta*-9-tetrahydrocannabinol and its stereochemical variants from synthetic origin, including dronabinol. Information on delta-9-tetrahydrocannabinol originating from the cannabis plant (Indian hemp) should be reported as a narcotic drug in Form C (Annual statistics of production, manufacture, consumption, stocks and seizures of narcotic drugs) in terms of cannabis resin or cannabis extract.

**III. Statistical data on substances in Schedule III and/or their salts**

(Kilograms)

|  | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| IDS Code | Substance | Quantity manufactured | Quantity used for the manufacture of non-psychotropic substances or products | Quantity used for the manufacture of preparations exempted under article 3, paragraphs 2 and 3 | Manufacturers’ stocks as at 31 December (voluntary) | Total  imports | Total exports | Quantity consumed |
| PA 002 | Amobarbital |  |  |  |  |  |  |  |
| PB 004 | Butalbital |  |  |  |  |  |  |  |
| PB 006 | Buprenorphine |  |  |  |  |  |  |  |
| PC 001 | Cyclobarbital |  |  |  |  |  |  |  |
| PC 009 | Cathine |  |  |  |  |  |  |  |
| PF 002 | Flunitrazepam |  |  |  |  |  |  |  |
| PG 001 | Glutethimide |  |  |  |  |  |  |  |
| PP 002 | Pentobarbital |  |  |  |  |  |  |  |
| PP 014 | Pentazocine |  |  |  |  |  |  |  |

**IV. Statistical data on substances in Schedule IV and/or their salts**

(Kilograms)

|  | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| IDS Code | Substance | Quantity manufactured | Quantity used for the manufacture of non-psychotropic substances or products | Quantity used for the manufacture of preparations exempted under article 3, paragraphs 2 and 3 (voluntary) | Manufacturers’ stocks as at 31 December (voluntary) | Total imports | Total exports | Quantity consumed |
| PA 001 | Amfepramone |  |  |  |  |  |  |  |
| PA 004 | Alprazolam |  |  |  |  |  |  |  |
| PA 005 | Allobarbital |  |  |  |  |  |  |  |
| PA 006 | Aminorex |  |  |  |  |  |  |  |
| PB 001 | Barbital |  |  |  |  |  |  |  |
| PB 002 | Benzfetamine |  |  |  |  |  |  |  |
| PB 003 | Bromazepam |  |  |  |  |  |  |  |
| PB 005 | Butobarbital |  |  |  |  |  |  |  |
| PB 007 | Brotizolam |  |  |  |  |  |  |  |
| PC 002 | Camazepam |  |  |  |  |  |  |  |
| PC 003 | Chlordiazepoxide |  |  |  |  |  |  |  |
| PC 004 | Clobazam |  |  |  |  |  |  |  |
| PC 005 | Clonazepam |  |  |  |  |  |  |  |
| PC 006 | Clorazepate |  |  |  |  |  |  |  |
| PC 007 | Clotiazepam |  |  |  |  |  |  |  |
| PC 008 | Cloxazolam |  |  |  |  |  |  |  |
| PC 016 | Clonazolam |  |  |  |  |  |  |  |
| PD 005 | Delorazepam |  |  |  |  |  |  |  |
| PD 006 | Diazepam |  |  |  |  |  |  |  |
| PD 013 | Diclazepam |  |  |  |  |  |  |  |
| PE 001 | Ethchlorvynol |  |  |  |  |  |  |  |
| PE 002 | Ethinamate |  |  |  |  |  |  |  |
| PE 003 | Estazolam |  |  |  |  |  |  |  |
| PE 004 | Ethyl loflazepate |  |  |  |  |  |  |  |
| PE 005 | Etilamfetamine |  |  |  |  |  |  |  |
| PE 009 | Etizolam |  |  |  |  |  |  |  |
| PF 001 | Fludiazepam |  |  |  |  |  |  |  |
| PF 003 | Flurazepam |  |  |  |  |  |  |  |
| PF 004 | Fencamfamin |  |  |  |  |  |  |  |
| PF 006 | Fenproporex |  |  |  |  |  |  |  |
| PF 011 | Flualprazolam |  |  |  |  |  |  |  |
| PF 012 | Flubromazolam |  |  |  |  |  |  |  |
| PH 001 | Halazepam |  |  |  |  |  |  |  |
| PH 002 | Haloxazolam |  |  |  |  |  |  |  |
| PK 001 | Ketazolam |  |  |  |  |  |  |  |
| PL 001 | Lefetamine (SPA) |  |  |  |  |  |  |  |
| PL 003 | Loprazolam |  |  |  |  |  |  |  |
| PL 004 | Lorazepam |  |  |  |  |  |  |  |
| PL 005 | Lormetazepam |  |  |  |  |  |  |  |
| PM 001 | Mazindol |  |  |  |  |  |  |  |
| PM 003 | Meprobamate |  |  |  |  |  |  |  |
| PM 008 | Methylphenobarbital |  |  |  |  |  |  |  |
| PM 009 | Methyprylon |  |  |  |  |  |  |  |
| PM 010 | Medazepam |  |  |  |  |  |  |  |
| PM 012 | Mefenorex |  |  |  |  |  |  |  |
| PM 016 | Midazolam |  |  |  |  |  |  |  |
| PM 018 | Mesocarb |  |  |  |  |  |  |  |
| PN 001 | Nimetazepam |  |  |  |  |  |  |  |
| PN 002 | Nitrazepam |  |  |  |  |  |  |  |
| PN 003 | Nordazepam |  |  |  |  |  |  |  |
| PO 001 | Oxazepam |  |  |  |  |  |  |  |
| PO 002 | Oxazolam |  |  |  |  |  |  |  |
| PP 004 | Phendimetrazine |  |  |  |  |  |  |  |
| PP 008 | Phenobarbital |  |  |  |  |  |  |  |
| PP 009 | Phentermine |  |  |  |  |  |  |  |
| PP 010 | Pipradrol |  |  |  |  |  |  |  |
| PP 015 | Pinazepam |  |  |  |  |  |  |  |
| PP 016 | Prazepam |  |  |  |  |  |  |  |
| PP 019 | Pyrovalerone |  |  |  |  |  |  |  |
| PP 020 | Pemoline |  |  |  |  |  |  |  |
| PP 024 | Phenazepam |  |  |  |  |  |  |  |
| PS 003 | Secbutabarbital |  |  |  |  |  |  |  |
| PT 003 | Temazepam |  |  |  |  |  |  |  |
| PT 004 | Tetrazepam |  |  |  |  |  |  |  |
| PT 005 | Triazolam |  |  |  |  |  |  |  |
| PV 001 | Vinylbital |  |  |  |  |  |  |  |
| PZ 002 | Zolpidem |  |  |  |  |  |  |  |

**Part two. Trade details: statistical data on imports and exports of substances in Schedules I, II, III and IV of the 1971 Convention**

**V. Trade details: import of substances in Schedules I and II, by country or region of origin**

(Kilograms)

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Specify substance →** |  |  |  |  |  |  |  |  |  |  |
| **Total →** |  |  |  |  |  |  |  |  |  |  |
| **Imported from: Quantities → Country or region ↓** |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |

**VI. Trade details: export of substances in Schedules I and II, by country or region of destination**

(Kilograms)

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Specify substance →** |  |  |  |  |  |  |  |  |  |  |
| **Total →** |  |  |  |  |  |  |  |  |  |  |
| **Exported to:  Quantities → Country or region ↓** |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |

**VII. Trade details: import of substances in Schedules III and IV, by country or region of origin**

(Kilograms)

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Specify substance →** |  |  |  |  |  |  |  |  |  |  |
| **Total →** |  |  |  |  |  |  |  |  |  |  |
| **Imported from: Quantities → Country or region ↓** |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |

**VII. Trade details: import of substances in Schedules III and IV, by country or region of origin (*continued*)**

(Kilograms)

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Specify substance →** |  |  |  |  |  |  |  |  |  |  |
| **Total →** |  |  |  |  |  |  |  |  |  |  |
| **Imported from: Quantities → Country or region ↓** |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |

**VIII. Trade details: export of substances in Schedules III and IV, by country or region of destination**

(Kilograms)

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Specify substance →** |  |  |  |  |  |  |  |  |  |  |
| **Total →** |  |  |  |  |  |  |  |  |  |  |
| **Exported to: Quantities → Country or region ↓** |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |

**VIII. Trade details: export of substances in Schedules III and IV, by country or region of destination (*continued*)**

(Kilograms)

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Specify substance →** |  |  |  |  |  |  |  |  |  |  |
| **Total →** |  |  |  |  |  |  |  |  |  |  |
| **Exported to: Quantities → Country or region ↓** |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |

**Part three. Statistical data on the use of substances in Schedules I, II, III and IV of the   
1971 Convention for the manufacture of other psychotropic substances**

**IX. Statistical data on the use of substances in Schedules I and II for the manufacture   
of other psychotropic substances**

(Kilograms)

|  |  |  |  |
| --- | --- | --- | --- |
| **Psychotropic substance used for the manufacture of  other psychotropic substance** | | **Other psychotropic substance derived from the  manufacturing process** | |
| ***Substance used*** | ***Quantity used*** | ***Substance derived*** | ***Quantity derived*** |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |

**X. Statistical data on the use of substances in Schedules III and IV for the manufacture   
of other psychotropic substances**

(Kilograms)

|  |  |  |  |
| --- | --- | --- | --- |
| **Psychotropic substance used for the manufacture of  other psychotropic substance** | | **Other psychotropic substance derived from the  manufacturing process** | |
| ***Substance used*** | ***Quantity used*** | ***Substance derived*** | ***Quantity derived*** |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |

1. [↑](#footnote-ref-2)